Abl Bio Inc.

Yuhan Corporation

Legochem Biosciences, Inc.

Toolgen Inc.

I-mab Biopharma US Limited

I-mab Biopharma Co., Ltd.

Yangsoon Lee

Hyejin Chung

Eunyoung Park

Yeunju Kim

Youngdon Pak

Kyeongsu Park

Byungje Sung

Eunsil Sung

Eun-Jung Lee

Kyungjin Park

Donghoon Yeom

Jinhyung Ahn

Yong-Gyu Son

Daehae Song

Jiseon Yoo

Eunjung Kim

Uijung Jung

Minji Park

Ui-Jung Jung

Sang Hoon Lee

Lei Fang

Bora Lee

Juhee Kim

Moo Young Song

Wenqing Jiang

Jaehyun Eom

Jaeho Jung

Na Rae Lee

Seawon Ahn

Young Bong Park

YoungKwang Kim

Weon-Kyoo You

Hyoju Choi

Yeryoung Yong

Wonjun Son

Jin-Soo Kim

Yong Zu Kim

Ho Young Song

Ju Young Lee

Jeiwook Chae

Sung Min Kim

Hyoung Rae Kim

Kyung Eun Park

Dae Hyuck Kang

Chang Sun Lee

Dong-Ki Lee

Yun-Hee Park

Ji Hye Oh

Jinwon Jung

Youngkwang Kim

Hyeun Joung Lee

Taewang Kim

JinWon Jung

Hyun Min Ryu

Sang-Jun Ha

Myeong Joon Kim

Ji-Na You

Chanmoo Lee

Junghyeon Hong

Youngeun Hong

Nara Han

Yeun Ju Kim

Jun Hyun Jeong

Mikyung Chang

Jaehyoung Jeon

Ju Yuel Baek

Junhyun Jeong

Young-Jae Yang

Provided are an antibody or antigen-binding fragment thereof that specifically binds to a B-cell maturation antigen (BCMA), a method of preparing the same, and use thereof. Accordingly, these can be utilized in effectively preventing or treating cancers.

Anti-BCMA antibody and use thereof

Provided are an anti-4-1BB/anti-HER2 bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

Anti-HER2/anti-4-1BB bispecific antibody and use thereof

Provided is an anti-4-1BB antibody or an antigen-binding fragment thereof, and uses thereof.

Anti-4-1BB antibody and use thereof

The present disclosure provides an anti-PD-L1/anti-4-1BB bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between 4-1BB and its ligand. The bispecific antibody may have high binding affinity to both of a PD-L1 protein and a 4-1BB protein.

Anti-PD-L1/anti-4-1BB bispecific antibodies and uses thereof

The present disclosure provides an anti-PD-L1/anti-LAG3 bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between LAG3 and its ligand (e.g., a MHC class II molecule and FGL1). The bispecific antibody may have high binding affinity to both of a PD-L1 protein (e.g., a human PD-L1 protein) and a LAG3 protein (e.g., a human LAG3 protein). Also provided are antibodies and fragments that have specificity to the PD-L1 or LAG3 protein alone, or antibodies and fragments having additional specificity to one or more other antigens.

Anti-PD-L1/anti-LAG3 bispecific antibodies and uses thereof

Provided are an anti-4-1BB/anti-EGFR bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

Anti-EGFR/anti-4-1BB bispecific antibody

The present invention discloses an anti-ROR1 antibody specifically recognizing human and mouse ROR1. The monoclonal antibody can be usefully used for cancer targeting treatment including detection of various cancer expressing ROR1 through specific binding, and drug delivery to specific cancer, etc. as well as a cancer therapeutic agent, by inhibiting tumors.

Anti-ROR1 antibody and use thereof

Provided is an anti-B7-H3 antibody specifically recognizing a B7-H3, which can be usefully as a cancer therapeutic agent, as having an inhibitory activity of an immune checkpoint which induces antibody-dependent cell-mediated cytotoxicity and T cell activation inhibited by B7-H3. In particular, the antibody having the inhibitory activity of an immune checkpoint can be used in combination with other immunoantibody therapeutic agents. In addition, it can be usefully used for cancer targeting treatment including detection of various cancers expressing B7-H3 through specific binding to B7-H3, and drug delivery to specific cancer, etc.

Anti-B7-H3 antibody and use thereof

The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.

Antibody-drug conjugate comprising antibody against human ROR1 and use for the same

The disclosure describes artificial chimeric transcription factors that include at least one zinc finger domain and that can regulate cellular differentiation, for example, a neuronal cell phenotype or an osteoblast phenotype.

Zinc finger transcription factor differentiation proteins

Growing community of inventors

Daejeon, South Korea

Yangsoon Lee